Developer docs
API playgroundTry for free, no card

Search company profiles

NeoNeuro

Full company profile

uuid000xrz3

Namestring
NeoNeuro
Legal namestring
NeoVentures Biotechnology Europe
Websiteurl
neoneuro-aptamers.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

NeoNeuro, doing business as NeoVentures Biotechnology Europe, is a privately held French biotechnology company founded in 2015 and headquartered in Villejuif (southern Paris suburbs), with 11-50 employees. The firm has built the Aptamarker Platform, an NGS-based high-plex proteomics technology that translates protein abundance into DNA abundance by applying a standardized library of 268 million aptamers to every sample, in contrast to the bottom-up, protein-by-protein probe construction used by other platforms. The company is positioned as an enterprise B2B service provider, monetizing custom proteomic analyses for pharmaceutical and biotechnology customers (preclinical patient stratification, cross-species biomarker work, drug development support including epitope and off-target analysis), research institutions and academia (high-plex biomarker discovery and cross-species profiling), and healthcare providers (personalized diagnostic profiling). GTM is consultative enterprise field sales with a quote-based pricing model and no publicly disclosed pricing. The company states that AI-enabled continuous learning and a future path to diagnostic (Dx) applications are central to its roadmap, and is publicly seeking investors and partners to scale.

Short descriptiontext

NeoNeuro (NeoVentures Biotechnology Europe) is a French private biotechnology firm operating the Aptamarker Platform, an NGS-based high-plex proteomics service applying 268 million aptamers per sample for pharmaceutical, biotech, research, and healthcare customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGeorges, France
HQ citystring
Georges
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
high-plex proteomics, aptamer-based diagnostics, biomarker discovery services, proteomic profiling platform, NGS proteomics analytics
Industry5 codes
1Proteomics & Mass Spectrometry Services
CodeHLAGANABPrimaryYes
2Proteomics & Biomarker Analytical Testing
CodeHLAGADAGPrimaryNo
3Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
CodeHLAAAMAJPrimaryNo
4Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
CodeHLAGAAADPrimaryNo
5Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
CodeHLAAAIAIPrimaryNo
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical and Diagnostic Laboratories6215
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Proteomics Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Aptamarker Platform Services
TypeProfessional Services
Description

The company provides proteomics analysis services through its Aptamarker Platform to pharmaceutical companies, biotech firms, and researchers for applications including preclinical patient stratification, biomarker discovery, treatment effect assessment, and drug development. Revenue is generated through service contracts with enterprise customers requiring proteomic analysis capabilities.

neoventures-eu.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Aptamarker Platform
Description

NGS-based proteomics platform with unprecedented depth for measurement of all forms of all proteins in all species. High-plex proteomics platform using 268 million Aptamarkers for biomarker discovery and characterization.

neoventures-eu.com
Core offering1 text field

NeoNeuro, doing business as NeoVentures Biotechnology Europe, provides aptamer-technology-based proteomics analysis services through its Aptamarker Platform. The platform applies 268 million standardized Aptamarkers to every biological sample and uses next-generation sequencing (NGS) read-out to deliver top-down, high-plex protein biomarker profiling in biological fluids or tissues. Services target pharmaceutical, biotechnology, research, and healthcare customers for preclinical patient stratification, cross-species biomarker analysis, treatment-effect assessment, and drug-development support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 268 million probes applied per sample versus several thousand with other platforms, enabling unprecedented proteomic depth.
+1 more record
Product overview1 text field

NeoVentures Biotechnology Europe offers a single unified platform called the Aptamarker Platform — an NGS-based proteomics platform that translates protein abundance into DNA abundance for high-throughput biomarker analysis. The platform uses 268 million standardized Aptamarkers applied to every sample, enabling deep multidimensional proteome characterization for applications including preclinical patient stratification, cross-species biomarker discovery, treatment effect assessment, and drug development.

Product and service1 record
1Aptamarker Platform
CategoryProteomics Services
Description

NGS-based proteomics platform that applies 268 million standardized Aptamarkers to every biological sample and uses next-generation sequencing read-out to deliver top-down, high-plex protein biomarker profiling in biological fluids or tissues. It is offered to pharmaceutical, biotech, research, and healthcare customers for preclinical patient stratification, cross-species biomarker discovery, treatment-effect assessment, and drug-development support.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
1Thermo Fisher Scientific (Proteomics)
TypeBroad incumbent
Description

Largest life-sciences instrumentation and proteomics services provider — incumbent offering broad proteomics workflows, MS-based services, and now Olink, giving it significant scale advantage over NeoNeuro.

2Olink (Olink Proteomics, part of Thermo Fisher Scientific)
TypeDirect peer
Description

Provides high-plex proximity-extension-assay proteomics services and products to pharma/biotech for biomarker discovery — directly comparable to NeoNeuro's high-plex proteomics service offering, though based on antibody-based PEA chemistry rather than aptamers.

3Evotec (Biopharma services & proteomics)
TypeBroad incumbent
Description

Large CRO/CDMO with proteomics and biomarker discovery services for pharma — competes for the same enterprise service contracts that NeoNeuro targets, with much greater operational scale.

4Alamar Biosciences
TypeDirect peer
Description

Ultrasensitive proteomics platform (NULISA / Firefly) for early disease detection and biomarker discovery including neurodegenerative indications — direct overlap with NeoNeuro's Alzheimer's and biomarker-discovery focus, though using antibody-based assays.

5Nautilus Biotechnology
TypeDirect peer
Description

Single-molecule, large-scale proteomics platform pursuing deep, unbiased proteome coverage for biomarker and drug-development applications — overlaps with NeoNeuro on the high-depth proteomics thesis, though via a different instrumentation approach.

6Seer
TypeDirect peer
Description

Proteomics platform (Proteograph) with engineered nanoparticles for deep, unbiased protein analysis at scale — competes in the same enterprise biomarker-discovery category as NeoNeuro's Aptamarker Platform.

7Quanterix
TypeEmerging player
Description

Ultra-sensitive immunoassay proteomics (Simoa) applied to neurodegenerative disease biomarkers — comparable business focus on Alzheimer's blood-based diagnostics and biomarker discovery, with broader validated assays.

8Standard BioTools (SomaScan)
TypeDirect peer
Description

Acquired SomaLogic, offering SomaScan high-plex aptamer-based proteomics assay serving pharma biomarker discovery — the most aptamer-proteomics direct precedent to NeoNeuro's approach and a useful commercial benchmark.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeoNeuro

Proteomics Servicesneoneuro-aptamers.com

NeoNeuro (NeoVentures Biotechnology Europe) is a French private biotechnology firm operating the Aptamarker Platform, an NGS-based high-plex proteomics service applying 268 million aptamers per sample for pharmaceutical, biotech, research, and healthcare customers.

What NeoNeuro does

NeoNeuro, doing business as NeoVentures Biotechnology Europe, is a privately held French biotechnology company founded in 2015 and headquartered in Villejuif (southern Paris suburbs), with 11-50 employees. The firm has built the Aptamarker Platform, an NGS-based high-plex proteomics technology that translates protein abundance into DNA abundance by applying a standardized library of 268 million aptamers to every sample, in contrast to the bottom-up, protein-by-protein probe construction used by other platforms. The company is positioned as an enterprise B2B service provider, monetizing custom proteomic analyses for pharmaceutical and biotechnology customers (preclinical patient stratification, cross-species biomarker work, drug development support including epitope and off-target analysis), research institutions and academia (high-plex biomarker discovery and cross-species profiling), and healthcare providers (personalized diagnostic profiling). GTM is consultative enterprise field sales with a quote-based pricing model and no publicly disclosed pricing. The company states that AI-enabled continuous learning and a future path to diagnostic (Dx) applications are central to its roadmap, and is publicly seeking investors and partners to scale.

NeoNeuro firmographics

Firmographics
Name
NeoNeuro
Legal name
NeoVentures Biotechnology Europe
Website
https://neoneuro-aptamers.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
NeoNeuro (NeoVentures Biotechnology Europe) is a French private biotechnology firm operating the Aptamarker Platform, an NGS-based high-plex proteomics service applying 268 million aptamers per sample for pharmaceutical, biotech, research, and healthcare customers.
Ownership category
akta.pro rank

NeoNeuro industry classification

Industry
Product category
Proteomics Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro primary industry
Proteomics & Mass Spectrometry Services (HLAGANAB)
akta.pro secondary industries
Proteomics & Biomarker Analytical Testing (HLAGADAG), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

  • High-plex proteomics
  • Aptamer-based diagnostics
  • Biomarker discovery services
  • Proteomic profiling platform
  • NGS proteomics analytics

Where NeoNeuro is headquartered

Location

Headquarters

HQ city
Georges
HQ country
France
HQ region
Europe

Offices1 record

Markets served

NeoNeuro business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Aptamarker Platform Services: The company provides proteomics analysis services through its Aptamarker Platform to pharmaceutical companies, biotech firms, and researchers for applications including preclinical patient stratification, biomarker discovery, treatment effect assessment, and drug development. Revenue is generated through service contracts with enterprise customers requiring proteomic analysis capabilities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

NeoNeuro product offering

Product offering

Core offering

NeoNeuro, doing business as NeoVentures Biotechnology Europe, provides aptamer-technology-based proteomics analysis services through its Aptamarker Platform. The platform applies 268 million standardized Aptamarkers to every biological sample and uses next-generation sequencing (NGS) read-out to deliver top-down, high-plex protein biomarker profiling in biological fluids or tissues. Services target pharmaceutical, biotechnology, research, and healthcare customers for preclinical patient stratification, cross-species biomarker analysis, treatment-effect assessment, and drug-development support.

Product overview

NeoVentures Biotechnology Europe offers a single unified platform called the Aptamarker Platform — an NGS-based proteomics platform that translates protein abundance into DNA abundance for high-throughput biomarker analysis. The platform uses 268 million standardized Aptamarkers applied to every sample, enabling deep multidimensional proteome characterization for applications including preclinical patient stratification, cross-species biomarker discovery, treatment effect assessment, and drug development.

Differentiator

Problem solved

Functional benefit

Brands

  • Aptamarker Platform: NGS-based proteomics platform with unprecedented depth for measurement of all forms of all proteins in all species. High-plex proteomics platform using 268 million Aptamarkers for biomarker discovery and characterization.

Products and services

  • Aptamarker Platform NGS-based proteomics platform that applies 268 million standardized Aptamarkers to every biological sample and uses next-generation sequencing read-out to deliver top-down, high-plex protein biomarker profiling in biological fluids or tissues. It is offered to pharmaceutical, biotech, research, and healthcare customers for preclinical patient stratification, cross-species biomarker discovery, treatment-effect assessment, and drug-development support.

Quantifiable outcome

  • 268 million probes applied per sample versus several thousand with other platforms, enabling unprecedented proteomic depth.
  • +1 more outcomes

Companies that use NeoNeuro

Customer profile

Segments3 records

Ideal customer profiles3 records

NeoNeuro technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

NeoNeuro partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights5 records

NeoNeuro competitors and assessment

Company assessment

Broad incumbents

  • Thermo Fisher Scientific (Proteomics): Largest life-sciences instrumentation and proteomics services provider — incumbent offering broad proteomics workflows, MS-based services, and now Olink, giving it significant scale advantage over NeoNeuro.
  • Evotec (Biopharma services & proteomics): Large CRO/CDMO with proteomics and biomarker discovery services for pharma — competes for the same enterprise service contracts that NeoNeuro targets, with much greater operational scale.

Direct peers

  • Olink (Olink Proteomics, part of Thermo Fisher Scientific): Provides high-plex proximity-extension-assay proteomics services and products to pharma/biotech for biomarker discovery — directly comparable to NeoNeuro's high-plex proteomics service offering, though based on antibody-based PEA chemistry rather than aptamers.
  • Alamar Biosciences: Ultrasensitive proteomics platform (NULISA / Firefly) for early disease detection and biomarker discovery including neurodegenerative indications — direct overlap with NeoNeuro's Alzheimer's and biomarker-discovery focus, though using antibody-based assays.
  • Nautilus Biotechnology: Single-molecule, large-scale proteomics platform pursuing deep, unbiased proteome coverage for biomarker and drug-development applications — overlaps with NeoNeuro on the high-depth proteomics thesis, though via a different instrumentation approach.
  • Seer: Proteomics platform (Proteograph) with engineered nanoparticles for deep, unbiased protein analysis at scale — competes in the same enterprise biomarker-discovery category as NeoNeuro's Aptamarker Platform.
  • Standard BioTools (SomaScan): Acquired SomaLogic, offering SomaScan high-plex aptamer-based proteomics assay serving pharma biomarker discovery — the most aptamer-proteomics direct precedent to NeoNeuro's approach and a useful commercial benchmark.

Emerging players

  • Quanterix: Ultra-sensitive immunoassay proteomics (Simoa) applied to neurodegenerative disease biomarkers — comparable business focus on Alzheimer's blood-based diagnostics and biomarker discovery, with broader validated assays.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

NeoNeuro social profiles

Digital presence

NeoNeuro financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeoNeuro leadership team

Management profile

Number of profiles

Profiles1 record

NeoNeuro funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeoNeuro M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeoNeuro

What does NeoNeuro do?

NeoNeuro, doing business as NeoVentures Biotechnology Europe, provides aptamer-technology-based proteomics analysis services through its Aptamarker Platform. The platform applies 268 million standardized Aptamarkers to every biological sample and uses next-generation sequencing (NGS) read-out to deliver top-down, high-plex protein biomarker profiling in biological fluids or tissues. Services target pharmaceutical, biotechnology, research, and healthcare customers for preclinical patient stratification, cross-species biomarker analysis, treatment-effect assessment, and drug-development support.

Is NeoNeuro a public or private company?

NeoNeuro is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NeoNeuro founded?

NeoNeuro was founded in 2015. It employs 11 to 50 people.

Where is NeoNeuro based?

NeoNeuro is headquartered in Georges, France, in the Europe region.

How does NeoNeuro make money?

One revenue line is on record: aptamarker Platform Services.

Who are NeoNeuro's main competitors?

Broad incumbents on record are Thermo Fisher Scientific (Proteomics) and Evotec (Biopharma services & proteomics). Direct peers are Olink (Olink Proteomics, part of Thermo Fisher Scientific), Alamar Biosciences, Nautilus Biotechnology, Seer and Standard BioTools (SomaScan). Quanterix is listed as an emerging player.

Does NeoNeuro have an API?

No public API is recorded for NeoNeuro.

What industry is NeoNeuro in?

NeoNeuro's product category is Proteomics Services. Its primary akta.pro industry code is HLAGANAB, Proteomics & Mass Spectrometry Services, with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales